Literature DB >> 33520362

Ese-3 contributes to colon cancer progression by downregulating EHD2 and transactivating INPP4B.

Junqiang Li1, Jing Yang1, Lei Hua1, Ronglin Wang1, Hong Li1, Chao Zhang1, Haihua Zhang2, Shanshan Li1, Liaoliao Zhu1, Haichuan Su1.   

Abstract

Epithelium-specific Ets protein 3 (Ese-3), a member of the Ets family of transcription factors, plays an important role in the development of cancers. However, little is known concerning its role in colon cancer (CC). In this study, we demonstrate that the expression of Ese-3 is upregulated in CC tissues and elevated Ese-3 expression is relationship with advanced T stage (P=0.037) and poor disease-free survival (DFS, P=0.044). Univariate and multivariate cox regression analyses show that Ese-3 expression may be an independent prognostic value for CC patients. Moreover, Ese-3 knockdown suppresses CC cell proliferation in vitro and in vivo, while Ese-3 overexpression has the opposite result. Further, we first demonstrate that EHD2 and INPP4B are the downstream genes of Ese-3. Subsequent investigation find that EHD2 is downregulated in CC tissues and knockdown of EHD2 significantly increase CC cell proliferation in vitro and vivo. Our findings reveal that Ese-3 promotes CC cell proliferation by downregulating EHD2 and transactivating INPP4B, and targeting the pathway may be a promising therapeutic target for CC patients. AJCR
Copyright © 2021.

Entities:  

Keywords:  EHD2; Ese-3; INPP4B; colon cancer; proliferation

Year:  2021        PMID: 33520362      PMCID: PMC7840712     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  4 in total

Review 1.  Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses.

Authors:  Jun Li; Dawei Chen; Minhong Shen
Journal:  Front Med (Lausanne)       Date:  2022-03-23

2.  TMEM43 promotes pancreatic cancer progression by stabilizing PRPF3 and regulating RAP2B/ERK axis.

Authors:  Junqiang Li; Yang Song; Chao Zhang; Ronglin Wang; Lei Hua; Yongdong Guo; Dongxue Gan; Liaoliao Zhu; Shanshan Li; Peixiang Ma; Cheng Yang; Hong Li; Jing Yang; Jingjie Shi; Xiaonan Liu; Haichuan Su
Journal:  Cell Mol Biol Lett       Date:  2022-03-08       Impact factor: 5.787

3.  EHD2 inhibits the invasive ability of lung adenocarcinoma and improves the prognosis of patients.

Authors:  Sheng Wei; Jingjing Shao; Jinming Wang; Tianye Zhao; Jia Liu; Xiying Shen; Yidan Wang; Haizhen Chen; Gaoren Wang
Journal:  J Thorac Dis       Date:  2022-07       Impact factor: 3.005

4.  Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF.

Authors:  Hongquan Wang; Shuang Wu; Yan Wang; Bo Tang
Journal:  Cancer Biol Med       Date:  2022-07-21       Impact factor: 5.347

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.